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In this issue of the Journal, Gold and colleagues (1) describe 
important observations concerning the use of the thrombin 
inhibitor argatrobao in patients with unstable aogina. Essen- 
tially, they noted that angina recurred in 21% of the patients, 
geoerally between 4 and 8 h after cessation of ergatroban 
therapy. This editorial discusses the clinical implications and 
potential mechanisms of this finding. 
Current Focus on Thrombin Inhibitors 
Role d Uuombin I  cardiac ewnts. Argatroban, a syn. 
thetic derivative of arginine, is one of several inhibitors of 
thrombin et various stages of preclinical development end 
clinical testing. These drugs are attracting interest for sev- 
eral reasons. First, it is now well established that coronary 
thrombus develops in the majority of acute myocardial 
infarctions and in many, perhaps most. cases of unstable 
angina (for review, see Ref. 2). Moreover, patients with 
unstable angina have elevated coronary sinus levels of the 
platelet products thromboxane AI and serotonin (Z), as well 
as elevated blood levels of Rbrinopeptide A (3), which is 
cleaved from fibrinogen when the latter is protealytically 
converted to fibrin by thmmbin. Heparin and aspirin have 
each reduced the mortality rate of myocardial infarction and 
of unstable aogina (4-7). further confirming the mle of 
thrombin and of olatelets in the oathoaenesis of these 
syndromes. In add;tion, thrombotic &occ&on has proved 
to be a limiting factor in approximately 5% of angioplasty 
procedures and 10% of thmmbulytic interventions in myo- 
cardial infarction (8). 
LimitationY of current MtItbmmbotic egents. Thus, a 
second reason for the current interest in thrombin is the 
recognition of the need for better aotitbrombotic regimens. 
For example, warfarin is slow to act, has little effect on the 
extrinsic pathway, most he taken oral& and interacts with 
many other dmgs. Recombinant tissue plasminogen activa- 
tor, by activating plasmin, activates the coagulation system 
by cleaving prothmmbin aad Factors V and X (9,lO:l. PIas- 
tin also activates platelets (see later) (II). Aspirin inhibits 
prosteglandin endoperoxide synthesis (cyctooxygenase). 
thereby inhibiting the formation of tbromboxane AZ, itself a 
platelet agonist and vaseconstrictor (12-14). However, other 
agonists such as thrombin. adenosioe diphosphate. seroto- 
oin. platelet activating factor, epinephrine and collagen are 
not inhibited by aspirin: these act not only through the 
phospholipase A pathway, bat also through phospholipase C 
and perhaps other pathways, thereby partially circumvent- 
ing the aspirin tiects p,lO,l9. Moreover, even relatively 
low doses of aspirin can inhibit cndothelial synthesis of 
orostacvclin (16). Ticlooidine has been aooroved bv the 
&od and Drug Admioi.&tioo for transient&heroic a&ks 
in asphin+ensitive patients but is bordencd with a slow 
onset of action and a small risk of oeutropenia (12). Heparin, 
which largely acts by accelerating the proteolytic ioactiva- 
tion of thrombin and activated Fector X by antithrombin III 
fl7,18), is at a disadvantage in established thrombosis be- 
cattle it is neutralized by platelet factor 4 and throrolwspon. 
din, and it has reduced ctlicacy against thrombht bound to 
fibrin or to platelets. Inaddition, heparin is a hctemgerteoos 
group of mokculQ extracted by a varkty of procedures and 
subject to lot to lot variability. Fioally, the requirement for 
aolithrombin III limits its utility in the of& patient 
with reduced levels of antIthm&in I11 (9.19). 
Rdedthrombh,k+cwmd&m uld&ekt-.A 
third reason for the recent~focus on thrhbin inhibitors is 
that it is now understood to be not only the tin ’ “tee in the 
conversion of fibrinogen to fibrin. hut also a key regttlamry 
steoftoaetharwith activationof Factor VII andlissttefactor. 
or’& Factor X) in the coagulation cascade. Moreover; 
thrombin plays a critical role in the amplification of the 
cascade, activating Factors V and XIII, which eventttally 
kads to the generation of more thrombin. In addition, 
thrombin activates Factor XIII to promote clot retractioo 
i20.20. These effects can all be demonstrated in vitro and, 
although the in viva regulation of this system is not yet 
completely understood, it is noteworthy that the high risk 
period after myocardial iofarction is characterized by ongo- 
ing, low grade activation of thromhitt (22). 
Finally, thmmbin is one of the most potent known 
agonists for platelet release and aggrcgatioa (20). Tltus, 
whereas any platelet inhibitor is an indirect inhibitor of 
coagulation (because plateler surfaces accelerate the wage- 
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lation enzyxxs and platelets promote stasis), thromhin is The Current Study 
directly inwlved in both the platelet and coaguk&n sys- Mecbaoirms 
terns. 
d-ed after 
The recent cloning of the plaIekt thmmbin receptor has 
buttoo. The report by Gold and colkqoes (I) in this issw 
indicated a unique mechanism of action (23). Thrombin ofthe Journal represents an important step in chamsterizing 
cleaves a specific sequence in the extracelhdardomain of the the clinical effects of agatmba AtIer a 4h intravenoos 
receptor, releasing a small peptide that serves as the ultimate infusion of 0.5 to 5 g&g per mio of argatrobao. 9 of 43 
ligand for the receptor. (An interesting inference is that, patients experienced an episode of aogioa. io most cases 4 to 
because trypsin activates the thrombin receptor and plzsmin 8 h after cessation of the iofosion. These episodes were 
has a similarly broad spectrum of action, it is likely that respasive to niwogtycerin and geoerally uncoolpliwred. 
plasmi~gen activators activate platelets by cleaving the Although some readers might be struck by the fact that all 43 
thmmbin receptor io addition to generating thrombin. Thus, patients were free of angina dwiog the iofusioo, the iovesti- 
it may Prove to be important to begin administration of gatators have taken a cautious approach and have emphasized 
antitbmmbin agents such as argatmban before starting the “rebound.” This term is used because of a fourfold 
thmmbalytic therapy). increase in concentration of thmmbiitithmmbin flf cam- 
A receptor of similar sequence has been cloned from rat plex at 2 h after infusion compared with the prettwtment 
smooth muscle cells, and it remains to be shown whether b-reline values. However. there was no r&otmd in levels of 
these differences are a function of the species or whether fibrinopeptide A. Whether the renewed angina after orgo- 
there are cell-specific thmmbin receptor isofoms (24). Such tmban infusion represents a true rebound or simply apn- 
a possibility is suggested physiologically by the difference in sents its recurrence after the withdrewat of thrombin inhibi- 
responsiveness of different types of endothelial cells to tion in some particularly refactory patients is not clear, 
thrombin (25). There is another thmmbin-bindii molecule However. the results do clearly demonstrate an importaot 
on platelet surfacc--GP lb, which activates pmtein kinase C mle for thrombs in the paihophysiology of unstable angina 
in response to van Willebraod factor (26). in humans. 
It is possible that these two receptors on platelets and Role of condnued generation ofthrombin and immwd 
cells. and this one catalytic site on thmmbin. mediate all of thrombin-anrirhrombin III complex. The data of Gold et al. 
tbmmbin’sactions: pmteolytic activation Factors II. V, VIII (I) indicate that one factor co&b&g to renewed .aogiw 
and XIII and protein C, platelet aggregation, woconstric- after argatroban iofusioo is the continued generation of 
tion. neotmphil adherence, monocyte chemotaxis. mitogen- thmmbin during the infusion. This obseruti~~~ suggests that 
esis for ettdotbeliat and smooth muscle cells and lympho- the positive feedback loop (wherein lhmmbin activates 
cytes, sod stimolatioo of production of prwacyclin platelet- Factors V and VIII, eventwily causiog activatioo of pro- 
activatiog factor, platelet-derived growth factor and nitric thrombin to thrombin) is not critical for the sustained gee- 
oxide (23). Thus. the e&cts of a thmmbin antagonist like eration of thnxnbii in patients tih unstabk angirt& Alter- 
arga(mban could be diverse. natively, thmmbin’s activatiw of fibrinogen may be mere 
Actiox~ of cameat thmgbio iokiMloR The thrombin completely inhibited thao that of Factors V and VIII by a 
inhibitors that have received the most attention are hirodin given dose of argatrobao. In addition 10 cootinoed genera- 
(a leech peptide whose sequence is similar to one near the tion of thrombin, a second factor in the thrombin- 
catalylic site of the tbrombin receptor) and the related aotithrombin III rebound cao be inferred from the data of 
hirulog and hien, as well as the synthctis inhibitors Eidt and colleagues (32), who reported that .w@rokw 
PPACK, EwP714 and argatroban. Experiments to date indi- displaces thromhin from antithmmbio III. ‘llw. as erga- 
cate that these inhibitors block roost if not att of thrombin’s troban is a competitive (reversible) inhibitor and is hugely 
actions. This observation is noteworthy because it was not cleared by I h, an increase in thmmbin-antithrombin IU 
obvious that the catalytic site and receptor site would be complex at the end of the info&n is to be expected. 
physically or functionally lied: Fibrin biis thrombin assuming that there are no dramatic changes in the binding 
without inhibiting thmmbin’s catalytic action and several or degradation of the thmmbinargatmbatt comp!ex. 
reports have indicated that thmmbin cao sewe as a mitogen Other thrombin-&ted mechanisms. Other mechanisms 
for smooth muscle cells, despite inactivation of the catalytic that may well contribute to the reactivatioo of angina after 
domain (27). Argatroban binds to a hydrophobic pocket near cessation of argatmban infusion inch& a possl&le up 
the catalytic site of thrombin with moderately high &inky regulation of thrombin receptors on the platelets, as platelet 
(28). Its K, for inhibition of catalytic activation of fibrinogen receptors are subjected to posttraoslatiooal w&tion by 
is 19 nhf, ami it is almost as potent h inhibition of platelet cyclic adenosiw monophosphate and cyclic guanosine 
aggregation (& 40 n&f) (29). Because argatroban is small and mottophosphate. lnbibitioa of tbmmbin may also prevent 
binds to a dllfennt binding site from that of fibrin, it inhibits thmmbio’s antitbmmbatic actions, which are mediated by 
clot-bound tbrombin just as hirodin does (301. In experimen- activation of protein C and stimulation of production of nitric 
ttd models of thrombolysis, argatrobao prevents thrombosis oxide and prostacyclio (19). 
and wcelerates lysis as wetI as or better than heparin (31). Role of cessation of hqwin therapy. Another mechanism 
that should be considered relates to the recent report by 
Theroux et al. (33) of a reactivation of angina 5 to I5 h after 
the cessation of heparin administration in patients with 
unstable angina. In the present study by Gold and cdleagues 
(i), six of the nine patients developing recurrent angina had 
been receiving hepatin until appronmateiy 4 h before arga- 
tmban infusion. In contrast, of the 34 patients who had no 
recurrent symptoms, only 12 had previously been taking 
hsparin. Thos, some of the xnctivation of angina in the 
present study might reflect discontinuation of the heparih is 
well. Moreover, increased clearance of antithrombin III 
durine heoarin infusion would tend to lower the baseline 
me&&ents of thrombin-antithrombin complex before ar- 
gatroban inrusion. By the time the complex was measured 
again (2 h after cessation of the infusion and 10 h after 
discontinuation of heparin). antithrombin 111 levels would 
be increasing. Thus, the calculated foulfold increase in 
thrombin-antithrombin III complex after argatroban may be 
in put tiifactual. 
Clittieal lmollcatiws of the current fInding. The clinical 
impdcations df these data are that iafusion~ of argatroban 
shouid not be discontinued abraotlv but should be tavered 
after beginning treatment With ispirin or another c&tive 
platelet inhibitor. Jang et al. (34) found that the addition of 
aspirin to mgatmban therapy acted to maintain arterial 
patency after thrombolytic therapy in a canine model. Fitz- 
gerald and Fitzgerald (31) found that addition of a thmmbox- 
ane A2 receptor antagonist to argatroban further reduced 
cyclic flow variations (attributed ID transient platelet agge- 
@ions and vasownstrictor respa~ses) in a canine model. 
However, concomitant aspirin therapy will not prevent 
the increase in thmmbin levels after discontinuation of 
argatroban. The increased thmmbin could activate platelets 
(through pathways not blacked by aspirin) and generate 
librin.‘Th;s. patients must be closkly imnitored for recur- 
rent ischemia during and after the administration of a throm- 
bin inhibitor, such as argatmban. In the canine model of 
cyclic flow variations, Eidt et al. (32) found that argatroban 
blocked cyclic flows only if given in the 1st 30 min to 2 h. 
When treatment was begun after 3 h of cyclic flows, the 
argatroban (and hcparin) were largely ineffective. However, 
cyclic flows were subsequently blocked by the addition of 
antagonists of the semtonin and lhromboxane AZ receptors. 
Thus, clinical studies need to be performed that evrduate the 
benefit &rded by the more direct thrombin antagonists 
when they are given relatively late after the onset ofunstable 
anghla. 
Inhibition of the final steps (platelet aggregation. forma- 
tion of fibrin) is naturallv attractive in a svstem with multiple 
and partialI; redundanipathways. Ho&r, as the m&c- 
ular defects in thrombosis are characterized, it may be 
possible to select specific therapies based on specific mech- 
anisms in individual patients. For example, it is c!xr that at 
least some patients with unstable angina have increased 
generation of serotonin and thromboxane AZ (2). Some 
patients with recurrent venous thrombosis have deficiencies 
in antithmmbin 111, elevated plasminogen activator inhibitor 
I or deficient protein C or protein S (22). Some patients after 
myocardial irfarction continue to generate thrombin and 
fibrin. High levels of fibrinogen, hematocrit, platelet aunt, 
Iw density lipoprotein and lipoprotein(a) appear to be risk 
factors for thrombosis (22). Thmmbosis itself probably cre- 
ates a local “hepxin deficiency” due to binding of cell 
surface heparan sulfate by thmmbin and degradation of 
hepamn by platelet-derived endoglycosidases (3%. How- 
ever, at the present ‘ime, individualized therapy is imprac- 
tical. Moreover, the likelihood is that multiple mechanisms 
are operating in many patients. These factors act to limit the 
et%acy of monotherapies as exemplified in this report by 
Gold et al. (I). Thus, in the foreseeable future, we are likely 
to be using double and triple therapy, with increasingly 
specific agents, to treat patients with unstable angina and to 
prevent its development in patients at risk. 
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